Contact:

Marc Panoff
Chief Financial Officer
Nephros, Inc.
Tel: 212-781-5113

FOR IMMEDIATE RELEASE
Todd Fromer or Garth Russell
KCSA Worldwide
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com

Nephros, Inc. Presenting at International
Renal Conferences

NEW YORK, June 1, 2005 – Nephros, Inc. (AMEX: NEP), announced today that it will be presenting its line of proprietary renal products at two international renal conferences in June 2005. Nephros believes that these conferences provide valuable central forums where Nephros can continue to build product recognition and inform the renal industry about the marked benefits of its therapy products.

From June 4-7, Nephros will be displaying its products at the European Renal Association / European Dialysis and Transplant Association (ERA/EDTA) Congress in Istanbul, Turkey. As the largest renal industry conference in Europe, each year the ERA/EDTA Congress draws physicians, administrators, nurses and other renal industry participants from around the world. The 2004 ERA/EDTA Congress in Lisbon, Portugal drew over 5,000 delegates, with over 1,100 attendees registering at the Nephros display.

From June 9-11, Nephros will display at the British Renal Society Conference in Manchester, UK, a forum drawing physicians from across the United Kingdom, including many of the physicians with whom Nephros is currently working in this territory. Nephros also displayed at this conference last year in Harrogate, UK.

A calendar of additional renal industry events at which Nephros will be participating in 2005 is available at Nephros’s website, www.nephros.com.

About Nephros, Inc.

Nephros, Inc., headquartered in New York, is a medical device company developing and marketing products designed to improve the quality of life for the End Stage Renal Disease (ESRD) patient, while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. Nephros believes that its products remove a range of harmful substances more effectively, and more cost-effectively, than existing treatment methods; particularly with respect to substances known collectively as “middle molecules,” due to their molecular weight, that have been found to contribute to such conditions as carpal tunnel syndrome, dialysis related amyloidosis, degenerative bone disease, and ultimately, to mortality in the ESRD patient.

Forward Looking Statements

This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may include statements regarding the efficacy and intended use of Nephros’s technologies under development, the timelines for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of Nephros. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) potential products that appeared promising in early research or clinical trials to Nephros may not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials; (ii) Nephros may not obtain appropriate or necessary governmental approvals; (iii) product orders may be cancelled, patients currently using Nephros’s products may cease to do so and patients expected to begin using Nephros’s products may not; (iv) Nephros may not be able to obtain funding if and when needed; (v) Nephros may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures; (vi) HDF therapy may not be accepted in the United States and/or Nephros’s technology and products may not be accepted in target markets; (vii) Nephros may not be able to sell its products at competitive prices or profitably; and (viii) Nephros may not be able to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros’s filings with the Securities and Exchange Commission, including Nephros’s Annual Report on Form 10-KSB filed with the SEC for the fiscal year ended December 31, 2004 and its Quarterly Report on Form 10-QSB filed with the SEC for the fiscal quarter ended March 31, 2005. Investors and security holders are urged to read those documents free of charge on the SEC’s web site at www.sec.gov. Nephros does not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

back to top ^